Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target
Siyu Deng, Mengna Wang, Chenglong Wang, et al.
Molecular Biology Reports (2022) Vol. 50, Iss. 1, pp. 577-587
Closed Access | Times Cited: 20

Showing 20 citing articles:

MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential
Junjiang Fu, Saber İmani, Mei-Yi Wu, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4723-4723
Open Access | Times Cited: 39
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Arefeh Zabeti Touchaei, Sogand Vahidi
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 28
p53/MicroRNA-34 axis in cancer and beyond
Wei Pan, Binshu Chai, Li Langping, et al.
Heliyon (2023) Vol. 9, Iss. 4, pp. e15155-e15155
Open Access | Times Cited: 20
Novel immunotherapies for breast cancer: Focus on 2023 findings
Huanrong Lan, Min Chen, Shi-Ya Yao, et al.
International Immunopharmacology (2024) Vol. 128, pp. 111549-111549
Closed Access | Times Cited: 5
Mechanisms of apoptosis-related non-coding RNAs in ovarian cancer: a narrative review
Yue Wang, Shirui Wang, Haiyan He, et al.
APOPTOSIS (2025)
Closed Access
The role of miR-16 and miR-34a family in the regulation of cancers: A review
Zahra Sadeghi, Mehrnoush Malekzadeh, Mohammadreza Sharifi, et al.
Heliyon (2025) Vol. 11, Iss. 4, pp. e42733-e42733
Open Access
MiRNA affects the advancement of breast cancer by modulating the immune system's response
Yeqin Fu, Qiuhui Yang, Ning Xu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 5, pp. 167759-167759
Closed Access
Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer
Luis M. Ruiz‐Manriquez, Cynthia Villarreal‐Garza, Javier A. Benavides‐Aguilar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9984-9984
Open Access | Times Cited: 10
Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy
Christoforos Vaxevanis, Michael Bachmann, Barbara Seliger
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 8, pp. e009774-e009774
Open Access | Times Cited: 2
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
Aditi Jain, Alan Barge, Christopher N. Parris
Oncogene (2024)
Open Access | Times Cited: 2
Comparing the Variants of Iron Oxide Nanoparticle-Mediated Delivery of miRNA34a for Efficiency in Silencing of PD-L1 Genes in Cancer Cells
Richa Pandey, Feng‐Shuo Yang, Vyshnav Punnath Sivasankaran, et al.
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 215-215
Open Access | Times Cited: 7
Pathological examination of factors involved in PD-L1 expression in patients with oral tongue squamous cell carcinoma
Yu Koyama, Chiharu Ogawa, Chihiro Kurihara, et al.
Maxillofacial Plastic and Reconstructive Surgery (2024) Vol. 46, Iss. 1
Open Access | Times Cited: 1
The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL
Alena Sophie Ehrmann, Alex Zadro, Eugen Tausch, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 13, pp. 1941-1953
Open Access | Times Cited: 1
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy
Seyed Esmaeil Ahmadi, Elahe Rahimian, Samira Rahimi, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer
Jing Li, Dianbao Zhang, Zhiwei Liu, et al.
Annals of Translational Medicine (2023) Vol. 11, Iss. 2, pp. 83-83
Open Access | Times Cited: 2
Deregulated MicroRNAs involved in P53 Signaling Pathway in Breast Cancer with Focus on Triple-negative Breast Cancer
Yasaman Naeimzadeh, Zahra Heidari, Vahid Razban, et al.
Current Molecular Pharmacology (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Tumor Suppressive Role of MicroRNAs in Triple Negative Breast Cancer
Acharya Balkrishna, Rashmi Mittal, Vedpriya Arya
Current Pharmaceutical Design (2023) Vol. 29, Iss. 42, pp. 3357-3367
Closed Access | Times Cited: 2
microRNAs expression profile in phyllodes tumors of the breast
Mohamed Hachana, Mouna Maâtouk, Zayneb Lassouad, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24803-e24803
Open Access
Master regulator: p53’s pivotal role in steering NK-cell tumor patrol
Haohao Wang, Qingjie Chen, Qinghua Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Liposome-Mediated MicroRNA Delivery: an Additional Layer of Gene Network Regulation and Nuclear Reprogramming
Navid Ghasemzadeh, Fatemeh Pourrajab, Ali Dehghani Firoozabadi, et al.
Deleted Journal (2024) Vol. 28, Iss. 5, pp. 245-254
Open Access
Page 1

Scroll to top